New Delhi, India, March 2026: ErlySign, the Nagpur-based biotech startup developing India’s first salivary biomarker–based screening test for early-stage cancer detection, today announced the appointment of Akshay Churi as Vice President, Manufacturing. The appointment comes as the company strengthens its leadership team to support the commercialisation and scale-up of its saliva-based early oral cancer detection technologies.
Akshay brings over two decades of experience in medical technology, biosciences, and precision manufacturing, having previously served as Business Manager at Husky Technologies for South-East Asia and Middle East, at ZAHORANSKY, and previously has over 13 years of experience building and scaling precision manufacturing programs, with strong expertise in mould development, project management, and strategic customer partnerships in the automotive sector.
At ErlySign, he will leverage this extensive experience to establish and scale the company’s manufacturing operations, including setting up a cleanroom facility, building and leading a high-performance team, securing regulatory approvals, and ensuring strong quality, compliance, and operational excellence standards while aligning plant performance and productivity with the company’s commercial growth objectives.
Commenting on the appointment, Shubhendra, Founder and CEO of ErlySign, said, “Akshay’s appointment aligns with our vision to expand access to affordable and scalable early cancer detection solutions. With his strong expertise in medical manufacturing and operational execution, we are confident he will strengthen our manufacturing readiness, enhance our go to market strategy, and help build key industry partnerships as we move toward commercialisation and global growth.”
Speaking about his new role, Akshay Churi said, “I am excited to join ErlySign at such a transformative stage. The company’s mission to make early cancer detection accessible and non-invasive has the potential to impact millions of lives. I look forward to building strong partnerships, scaling our solutions, and contributing to a healthcare ecosystem focused on prevention and early diagnosis.”
Through this appointment, ErlySign reinforces its commitment to building a strong leadership team capable of driving innovation, scalability, and global outreach. The company continues to position itself as a pioneer in saliva-based diagnostics, advancing its journey to deliver accessible, accurate, and patient-friendly cancer screening solutions.
ErlySign is a biotechnology startup focused on developing salivary biomarker–based diagnostic technologies for early cancer detection. The company is working to build accessible, non-invasive, and scalable cancer screening solutions aimed at improving early diagnosis and patient outcomes.
By combining biotechnology innovation with scalable diagnostic infrastructure, ErlySign is advancing the development of saliva-based screening tools designed to enable earlier detection of oral cancer and support preventive healthcare initiatives.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
